BSECCME GLOBAL LIMITED· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 1 Sept, 2026 · 17:40 IST

Clarification on typo errors in board meeting outcome filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-5.0%Reaction day
₹35.91
prior close
₹34.12
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-4.4% vs market
Biotechnology peers, median of 5sector-1.0%-4.0% vs sector

On the reaction day the stock moved 4.4 pts less than Nifty Microcap 250 and 4.0 pts less than its Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
+0.0
15m
+0.0
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-5.0-0.6-4.4-1.0-4.0
Next day
-9.7+0.0-9.7+2.2-11.9
2d
-14.2+0.7-14.9+0.9-15.1
3d
-18.5+1.1-19.6+3.0-21.5
4d
-22.6+1.6-24.2+4.0-26.6
5d
-21.9+1.5-23.4+1.8-23.7
1w
-16.5+1.4-17.8-0.8-15.6
15d
+22.3+0.4+21.8——
1m
+9.8-1.4+11.2-7.6+17.4
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Biotechnology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

CCME Global clarified two typo errors in its August 29, 2026 board meeting filing to BSE. First, 'CCME UAE' should read 'Interlink' referring to Interlink Distribution LLC. Second, 'INR AED' should be just 'AED' since Interlink's share capital is AED 1,00,000. The underlying deal involves allotting about 2.03 crore equity shares to Mr. Mostafa Ahmed Kabir (Non-Promoter) for acquiring 52 percent stake in Interlink Distribution LLC. All other details in the original filing remain unchanged.

Likely market impact

No material impact - only typographical corrections. The preferential issue for Interlink acquisition remains unchanged.